Sign In
18 Nov 2011 08:40
ο»Ώ
For Immediate Release | 18 November 2011 |
Β
Β
Sphere Medical Holding plc
Β
Completed Second Admission to AIM
Β
Cambridge, UK, 18 November 2011: Sphere Medical Holding plc (AIM:SPHR.L) ("Sphere Medical" or the "Company") is pleased to announce that Admission and trading of 18,943,843 additional Ordinary Shares commenced today on the AIM market of the London Stock Exchange ("AIM"). The First Admission of 17,861,801 Ordinary Shares took place on 17 November 2011. Following Second Admission, the Company's enlarged issued share capital is 36,805,644 ordinary shares.
Β
Peel Hunt LLP is nominated adviser and broker to the Company.
Β
Sphere Medical's TIDM Code is SPHR.L and its ISIN number is GB00B551W951.
Β
Β
For further information, please contact:
Β
Sphere Medical Holding plc | Tel: +44 (0)1223 875222 |
Dr Stuart Hendry, Chief Executive Officer | |
Matthew Hall, Chief Financial Officer | |
Peel Hunt LLP | Tel: +44 (0) 20 7418 8900 |
James Steel Matthew Armitt / Dr Vijay Barathan Harry Florry | |
Buchanan | Tel: +44 (0) 20 7466 5000 |
Tim Anderson | |
Lisa Baderoon |
www.spheremedical.com
Β
About Sphere Medical
Sphere Medical is a UK based medical device company completing the development of a range of monitoring and diagnostic products designed to provide significant improvements in patient management in a number of hospital specialties. Sphere Medical's products are expected to allow near real time measurement of blood gases, various electrolytes and drug levels with laboratory accuracy, at the patient's bedside. This information can be used in a wide range of medical applications and is intended to enable faster clinical decision making and consequently to improve the management of patients.
Β
Sphere Medical's two most advanced products, based on its proprietary microanalyser platform technology, are a disposable patient-attached arterial blood analyser for use in the Intensive Care Unit and Operating Room ('Proxima') and a device for continuous blood monitoring in the bypass circuit in patients undergoing cardiopulmonary bypass surgery ("CPB device"). Sphere Medical has also developed a device ('Pelorus 1000') that can measure blood levels of the intravenously administered anaesthetic drug, propofol. In each case, these products will ultimately target patients requiring close monitoring and frequent levels of blood testing.
Β
Sphere employs 43 staff in the areas of research and development, product development, sales and marketing and management and operations at its premises at Harston, Cambridge, UK.
Follow the stocks
